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ABSTRACT 
Heart failure (HF) and type 2 diabetes mellitus (T2DM) are both growing public health 
concerns contributing to major medical and economic burdens to society. T2DM increases 
the risk of HF, frequently occurs concomitantly with HF, and worsens the prognosis of HF. 
Several anti-hyperglycemic medications have been associated with a concern for worse HF 
outcomes. More recently, the results of the EMPAREG OUTCOME trial showed that the 
sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin was associated with a 
pronounced and precocious 32% reduction in cardiovascular mortality in subjects with T2DM 
and established cardiovascular disease. These benefits were more related to a reduction in 
incident HF events rather than to ischemic vascular endpoints. Several mechanisms have 
been put forward to explain these benefits, which also raise the possibility of using these 
drugs as therapies not only in the prevention of HF, but also for the treatment of patients 
with established heart failure regardless of the presence or absence of diabetes.  Several 
large trials are currently exploring this postulate.   
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Heart failure (HF) is a global health problem with a prevalence of ~26 million worldwide. 
Patients with HF are at a 40%-50% risk of mortality within five years of diagnosis,1 and suffer 
from recurrent hospitalizations and poor quality of life. Type 2 diabetes mellitus (T2DM) is 
growing with a prevalence of over 400 million globally.2 The deleterious effects of T2DM can 
be separated into microvascular (neuropathy, nephropathy, retinopathy) and macrovascular 
(coronary disease, stroke, peripheral arterial disease) complications. While there is 
moderate to high quality evidence that glucose control reduces the risk of microvascular 
complications, its beneficial effect on macrovascular complications are less apparent and 
appear to take longer to manifest.3 Cardiovascular diseases (CVD) account for approximately 
half of the deaths in T2DM.4 CVD, HF, and T2DM are all associated with chronic kidney 
disease (CKD), which together further worsen prognosis.5, 6 
There is now an increased recognition of the association between HF and T2DM,7 
with increasing prevalence of patients with both diseases concomitantly. The patients with a 
concomitant disease have a worse prognosis compared to those with either disease alone. 
HF is more than twice as likely to develop in patients with T2DM and may develop 
independent of coronary disease.8 Conversely, HF is associated with insulin resistance and a 
higher risk for developing T2DM.9 The prevalence of T2DM among patients with HF is as high 
as 40-45%10 and the prevalence of HF in patients with T2DM is reported to be 10-23%.11 Indeed, 
HF was the second most common initial CVD presentation in patients with T2DM, at 14.1%.12 
The results of the recently published EMPA-REG OUTCOME trial, with the sodium-
glucose cotransporter 2 (SGLT2) inhibitor, empagliflozin hold promise for CV risk reduction in 
diabetes. Particularly intriguing are the potential benefit with regards to HF. The current 
review aims to examine the potential role of this class of drugs in patients with HF with and 
without DM. 
 
HEART FAILURE OUTCOMES IN DIABETES MELLITUS CLINICAL TRIALS  
In 2008, the US Food and Drug Administration (FDA) put forth guidelines for drug 
manufacturers to demonstrate that new anti-hyperglycemic medications should not 
increase the risk for CVD, with a focus on cardiovascular death, myocardial infarction, or 
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stroke.13 Until recently, there was no evidence for HF risk reduction; conversely there were 
some concerns of worsening HF risk with therapies targeting glucose control.14 For example, 
several trials showed an increased risk of HF with thiazolidinediones,15 16 thus these agents 
are not recommended in patients with HF.17 Interestingly, the dipeptidyl peptidase 4 
inhibitor (DPP4i) saxagliptin and alogliptin but not sitagliptin may increase the risk of HF.18 
Sulfonylureas have been associated with increased risk of developing HF, but most data 
were derived from observational studies and definitive prospective trials are needed.19, 20 
 
The EMPA-REG OUTCOME Trial 
The EMPA-REG OUTCOME trial was the first trial to show cardiovascular mortality 
reduction in high-risk patients with T2DM treated with empagliflozin, an SGLT2 inhibitor. This 
trial randomized 7020 patients with T2DM and CVD to 10mg or 25mg of empagliflozin daily or 
to placebo.21 The primary endpoint of death from cardiovascular causes, nonfatal myocardial 
infarction, or nonfatal stroke was seen in 10.5% in the pooled empagliflozin group vs. 12.1% 
with placebo (hazard ratio [HR] 0.86; 95% confidence interval [CI], 0.74 to 0.99; P=0.04) in 
the 3.1 year follow up period. There were no significant differences in rates of myocardial 
infarction or stroke but there was a 38% lower risk of cardiovascular death and 32% risk 
reduction in all-cause death (both P<0.001) with empagliflozin.  
Empagliflozin overall reduced the risk for HF hospitalization by 35% and HF death or 
hospitalization by 39% (both P<0.001), with benefits seen in both patients with and without 
documented HF at baseline.22 The reduced adjudicated endpoint of HF hospitalization was 
supported by similar reductions of investigator reported HF, and the introduction of loop 
diuretics (as a surrogate for HF). The prevalence of manifest HF at baseline was 10% in the 
trial. HF ascertainment was based on self-reports without characterization of functional 
class, ejection fraction, or biomarker data. Detailed HF phenotyping, including 
echocardiography, was not performed in the EMPA-REG OUTCOME trial and it is unclear 
whether the HF-related benefits seen were limited to development of HFrEF or HFpEF. 
When compared with other hypertension,23-27 HFpEF28-32 and HFrEF33-35 trials, the mortality 
and HF hospitalization rates in the EMPA-REG OUTCOME trial are comparable to other high 
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risk population trials, and the event rates among those who had baseline HF were 
comparable to those observed in HFpEF trials. (Figure 1A and B) This may suggests 
unsuspected high prevalence of HF in this population at baseline. This also raises the 
possibility that among those with HF-associated endpoints in this study, there perhaps may 
be more patients with HFpEF compared to those with HFrEF. This is consistent with what 
prior epidemiological studies suggesting an increase in HFpEF in patients with T2DM. This 
work is also consistent with rising evidence of a link between obesity, renal disease and 
HFpEF.36  
 
DISSOCIATION BETWEEN GLUCOSE CONTROL AND HEART FAILURE OUTCOMES 
Interestingly, there was no significant relationship between glycemic control and HF 
outcomes in the EMPA-REG OUTCOME trial. Both the 10mg and 25mg doses had similar 
effects on outcomes. HbA1c level at randomization was not a determinant of benefit and 
patients across the spectrum of initial HbA1c values benefited from the treatment with 
empagliflozin. Similarly, HF patients who had a larger (≥0.3%) vs. a more modest (≤0.3%) 
reduction in HbA1c benefited equally from empagliflozin.37 These observations suggest that 
the benefit with this agent is not related entirely to glucose control per se and other 
mechanisms mediate its cardiovascular-protective effects. It is noteworthy that another 
class of drug, glucagon-like peptide-1 (GLP-1) receptor agonist liraglutide and semaglutide, 
were effective in lowering HbA1C and significantly improved other cardiovascular outcomes 
but not HF events.38-40 However, when used in patients with stable chronic HF with or 
without DM, liraglutide was associated with higher cardiac adverse events.41 
 
MECHANISM OF ACTION OF SGLT2-INHIBITORS FOR GLUCOSE CONTROL 
SGLT2 is located almost exclusively in the kidney, while SGLT1 transporters are also located 
in the intestines, heart, and skeletal muscles.42 Glucose reabsorption in the kidneys occurs in 
a sodium-dependent manner via SGLT proteins, with most reabsorption occurring at the 
proximal convoluted tubule through SGLT2 and a smaller portion in the distal segment of 
the proximal tubule by SGLT1.43 Once the maximum glucose transport capacity has been 
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reached, excess glucose is excreted into the urine. SGLT2 inhibitors lead to increased urinary 
glucose excretion by blocking SGLT2-mediated glucose reabsorption. (Figure 2)  
 
POTENTIAL MECHANISM BENEFITING HEART FAILURE 
While the exact mechanism by which empagliflozin may impact HF outcomes is not 
understood, several effects of SGLT2 inhibitors can potentially be of benefit. Any potential 
mechanism of SGLT2 inhibitors benefiting HF should take into account the simultaneous 
reduction of CV mortality and the very rapid reduction of HF and cardiovascular mortality as 
well. (Figure 3, partially adapted from 44) 
 
Lowering Blood Pressure: Treatment with an SGLT2 inhibitor is associated with reduction in 
systolic and diastolic blood pressure. Unlike vasodilators, this change in blood pressure is 
not associated with an increase in heart rate45, suggesting that the sympathetic nervous 
system is not activated.46 Reduction in blood pressure is likely multifactorial related to 
natriuresis, reduced plasma volume, non-fluid weight loss, as well as direct vascular 
effects.47 
 
Sodium and Fluid Loss: SGLT2 inhibitors induce osmotic diuresis and natriuresis through the 
decreased reabsorption of glucose and sodium, 48 resulting in less extracellular volume, 
possible reduction of vascular wall stress, improving cardiac function and potentially 
reducing congestion. Reduction in plasma volume may also lead to reduced myocardial 
stretch and natriuretic peptide levels,44, 49 as well as improving symptom and functional 
capacity. Loop and thiazide diuretics work primarily by natriuresis, whereas vaptans mediate 
their effects via aquaresis. In contrast, SGLT2 inhibitors induce natriuresis as well as osmotic 
diuresis via glucosuria. The increase in sodium excretion is temporary,50 thus the mechanism 
might be an initial reduction of whole body sodium content. This then translates into a 
benefit via hemodynamic effects as well as an effect on sodium content within 
cardiomyocytes, i.e. an increase in sodium in these cells favors arrhythmias in HF models.51 In 
addition, compared with conventional osmotic diuretics, empagliflozin does not affect 
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plasma osmolality. While both SGLT2 inhibitors and thiazide-like diuretics work on the 
proximal tubule of the nephron, thiazides are associated with hypokalemia, increased serum 
uric acid, and impaired glucose tolerance while SGLT2 inhibitors are not associated with 
increased serum uric acid or impaired glucose tolerance and no changes in serum potassium 
levels occur.52 
Under physiologic concentrations of glucose, SGLT2-mediated glucose uptake 
stimulates the sodium-hydrogen exchanger (NHE)3, involved in the reabsorption of sodium 
bicarbonate, while supra-physiologic glucose levels inhibit NHE3, inducing natriuresis .53, 54 In 
a HF rat model, the up-regulation of NHE3 likely contribute to attenuation of the natriuresis 
and volume expansion.55 SGLT2 inhibitors result in decreased activity in NHE3, possibly 
contributing to natriuresis, and reduction in blood pressure.56 
 
Effects on the Renin Angiotensin System:  Under physiologic conditions, the majority of 
sodium is reabsorbed in the proximal tubule. This enables the macula densa, located at the 
transition between the ascending limb of the loop of Henle and the distal convoluted tubule 
to sense changes in sodium concentration and adjust glomerular filtration rate via 
tubuloglomerular feedback. The decrease in sodium delivery to the distal tubule leads to a 
compensatory increase in renin by the juxtaglomerular cells and activation of the 
downstream angiotensin system.48 In the setting of HF, decreased renal blood flow leads to 
sodium reabsorption via the proximal tubule, likely enhanced by SGLT2 augmented by 
activation of the sympathetic nervous system and angiotensin II.57, 58 While inhibition of 
SGLT2 may attenuate the downstream effects of neurohormonal activation in HF,59 other 
studies suggest that in response to volume contraction, the levels of aldosterone and 
angiotensin II, may actually increase in response to SGLT2 inhibition.42 
 
Weight Loss: Compared to some other anti-diabetic agents, SGLT2 inhibitors are associated 
with reduction in body weight.60 This occurs rapidly initially and then gradually until a 
plateau is reached and it is sustained over time. The initial decline is thought to occur as a 
result of osmotic diuresis; however the subsequent gradual and predominant weight 
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reduction is likely caused caloric urinary glucose loss resulting in reduction in visceral fat 
mass.61 There is ample evidence that obesity per se is a strong risk factor for incident HF but 
whether weight loss and the method of weight loss influence outcomes in patients with 
manifest HF,62 or those with diabetes,63 remains controversial.  
 
Maintenance of Kidney Function: Decline in renal function is accompanied by disruption in 
volume homeostasis and predisposition to progression of HF.64 More recently, renal 
dysfunction has been proposed as a potential causal risk factor for HFpEF.36 Albuminuria is 
an important marker of vascular resistance and progression of kidney disease.65 SGLT2 
inhibitors reduce urinary albumin excretion and potential preservation of glomerular 
filtration rate over time. Recently Wanner et al reported relevant data from EMPA-REG 
OUTCOME trial.66 New onset or worsening of nephropathy, a pre-specified exploratory 
composite renal endpoint, was reduced by 39%. Compared with placebo, empagliflozin 
significantly reduced the initiation of renal replacement therapy by 55%, doubling of serum 
creatinine by 44%, and new onset of macroalbuminuria by 38%. Empagliflozin also 
significantly slowed the decline in estimated glomerular filtration rate over time compared 
with placebo. It is important to note that these renal effects occurred on the background of 
renin-angiotensin-aldosterone system blockers for renal protection. 47, 66 The preservation of 
renal function by empagliflozin may contribute to its beneficial effects on HF. It should also 
be noted that while the GLP-1 receptor agonists also lessened albuminuria, their effects on 
other renal outcomes appear less clear.38, 39 In T2DM where there is increased glucose and 
sodium reabsorption via SGLT2, decreased sodium delivery at the distal tubule results in 
afferent arteriole vasodilation leading to an increase in glomerular filtration rate, which is 
also known as “hyperfiltration”. Chronic hyperfiltration contributes to nephron loss. The 
target of SGLT1 inhibitors (either for selective SGLT1 inhibitors or for combined SGLT1+SGLT2 
inhibitors) is the intestinal SGLT1.These SGLT1 inhibitor-compounds do not reach a 
concentration in the renal tubules that would allow for a renal inhibition of SGLT1. Therefore, 
for renal hemodynamics, the SGLT1 inhibition part is negligible regarding renal 
hemodynamics, for all currently available compounds. Regarding urinary glucose excretion 
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(UGE), this is relatively comparable between selective and non-selective SGLT inhibitors and 
both are associated with reduced UGE in patients with chronic kidney disease. 
 
Reduced Uric Acid and Oxidative Stress: Elevations in uric acid is associated with oxidative 
stress and increased reactive oxygen species, increase in numerous cytokines, activation of 
the renin angiotensin system, and hypertension.67, 68 SGLT2 inhibitors result in reduction in 
uric acid levels.69 In animal studies, empagliflozin reduced oxidative stress.70 Given the 
association of uric acid on both the renal and CV systems, this may be a mechanism for the 
impact of SGLT2 inhibitors on HF.  
 
Increased Hematocrit: SGLT 2 inhibitors also result in increased hemoglobin and hematocrit 
levels.71 Univariate analysis of potential mediators for empagliflozin's CV mortality benefit 
demonstrated that hematocrit showed a 52% change in the hazard ratio for CV mortality.72 
This may be related to hemoconcentration of plasma volume, as discussed above. SGLT2 
inhibitors ameliorate tubulointerstitial hypoxia through reduction in proximal tubule 
workload, though evidence for this theory is currently limited to animal models.73 This allows 
for stimulation of erythropoiesis, which may partially explain the observed increase in 
hematocrit. However, the increase in erythropoietin is transient while the change in 
hematocrit is sustained over time.74 Hemoglobin provides better tissue oxygenation and is 
regulated through hypoxia-inducible factor 1-alpha expression and subsequent 
erythropoietin secretion, factors influenced by SGLT2 inhibitors.75 
 
Decreased Inflammation: SGLT2 inhibitors have been shown to reduce biomarkers of 
inflammation in animal models.76 In a rat model, the anti-inflammatory effects may be 
mediated through inhibition of NADPH oxidase activity and decreased formation of 
advanced glycation end products.70 This may benefit both the sequelae of T2DM and HF 
such as vascular dysfunction and fibrosis.70  
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Decreased Arterial Stiffness: Increased arterial stiffness is a predictor of HF events and death 
and is associated with hypertension, obesity, and worse HF.42 Empagliflozin has been shown 
to reduce arterial stiffness in patients with type I DM.46 This may be related to weight loss, 
improved arterial compliance and smooth muscle relaxation through a negative sodium 
balance,46 which may be of particular benefit in HFpEF. In patients with T2DM and 
hypertension, empagliflozin was associated with reductions in markers of arterial stiffness 
and vascular resistance.77 The reduction in arterial stiffness via SGLT2 inhibition, coupled 
with improved myocardial energetics and calcium handling could act together to improve 
HF.78 Improvement in myocardial energetics would likely mean that systolic wall stress is 
shifted earlier rather than later, which is what is seen in HF. Thus, myocardial-arterial 
coupling improves. At the same time, the cardiomyocytes are less vulnerable to stress 
because of improved calcium handling.  
 
Metabolism: SGLT2 inhibition increases glucagon levels.79 In addition to its role in glucose 
homeostasis, glucagon also acts as a stress hormone.80 Glucagon receptors expressed on 
cardiac myocytes facilitate its positive inotropic and chronotropic effects on the heart.81 In 
the setting of T2DM, the hyperglycemic state results in increased glucose uptake by cardiac 
myocytes beyond its oxidative capacity (glucotoxicity), impairing cardiac function.61 SGLT2 
inhibitors as well as metformin decrease excess glucose uptake by the heart, albeit through 
different mechanisms.61 Under normal circumstances, the heart is primarily fueled by fatty 
acids. In the setting of diabetes, the hyperglycemic state results in increased glucose uptake 
by cardiac myocytes, impairing cardiac function.61 The elevated level of beta 
hydroxybutyrate seen with SGLT2 inhibitors82 results in a shift in fuel supply from fatty acids 
and glucose, which are less energy efficient in the setting of T2DM, towards the more 
energy-efficient ketones. This in turn improves myocardial and renal metabolic efficiency 
while reducing oxygen consumption.83, 84 This ketone hypothesis, however, is currently 
under study.85 
  
POTENTIAL BENEFIT ACROSS THE SPECTRUM OF HEART FAILURE 
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The exact mechanisms by which empagliflozin lowers the risk of cardiovascular death in 
patients with T2DM and might influence HF outcomes are not clearly understood. Most of 
the pharmacodynamic effects of SGLT2 inhibitors have the potential to reduce the 
development and progression of both HFrEF and HFpEF.86 Thus, the potential for benefit 
with these agents should be properly tested across the left ventricular ejection fraction 
spectrum in patients with HF in carefully designed, randomized controlled trials with 
sufficient statistical power.  Importantly, since the HF benefit of SGLT2 inhibitors does not 
seem to be related to glucose control and these agents are associated with low rates of 
hypoglycemia in states of normal glucose concentration, it is rational to postulate that 
SGLT2 inhibitors might be both safe and effective in HF patients without DM as well. In fact, 
in a zebrafish HF model, empagliflozin was able to attenuate HF in the absence of 
hyperglycemia.87 
One unifying hypothesis is that the dominant mechanism of action of empagliflozin is 
a glucouretic effect without the usual adverse effects of conventional diuretics. In the 
EMPA-REG OUTCOME trial, the early, sizeable and persistent effect of empagliflozin in 
raising hematocrit and serum albumin, a drop in blood pressure, and a decrease in body 
weight may be interpreted as the effect on plasma volume and hemoconcentration, 
resulting from a benign “smart” or “diabetes-directed” diuretic effect. Indeed, this 
glucouretic effect is a striking variance with those observed with all other diuretics. The 
apparently adverse effects inherently associated with the pharmacology of the conventional 
loop diuretics and thiazides used in HF may counter and/or dampen their potential survival 
benefits. Still, other mechanism such as changes in cardiac metabolisms by SGLT2 inhibitor 
treatment may also contribute to beneficial effects in HF. In addition to clinical trials, further 
laboratory experimental data are warranted to further elucidate the underlying mechanisms 
of cardioprotection. 
 
CLASS EFFECT OF SGLT2 INHIBITORS 
While empagliflozin has demonstrated a reduction in cardiovascular death and HF 
hospitalization risks, these analyses need to be replicated with other SGLT2 inhibitors before 
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it can be ascertained if this is a class effect or a drug-specific effect. In the near future, 
studies with canagliflozin and dapagliflozin will also report cardiovascular outcome results, 
shedding further light on this issue.88, 89  
 
FUTURE DIRECTION 
The EMPA-REG OUTCOME trial was designed to study high-risk T2DM patients. This trial 
was not designed to assess the benefits of empagliflozin in patients with HF. Only a distinct 
minority of these patients (~10%) had a history of HF. Secondary analyses of the HF sub-
group provides interesting hypotheses for potential benefits of this drug in HF; however the 
strength of evidence is not sufficient to recommend its use for the treatment of patients 
with HF and none of the HF guidelines currently recommend it for HF treatment. There have 
been examples in the past of cardiovascular drugs that have benefited patients with T2DM 
and CVD and were also shown to be of benefit in observational studies in HF. However, 
when dedicated adequately powered HF trials were done, no benefit was seen in improving 
HF outcomes.  
A full characterization of the HF population, including information regarding left 
ventricular ejection fraction was not performed in the EMPAREG OUTCOME trial, as this was 
not a HF study. None of the therapies shown to improve survival in patients with HF with 
reduced ejection fraction, such as angiotensin-converting enzyme inhibitors or beta-blockers 
or mineralocorticoid antagonists have been conclusively shown to improve outcomes in 
patients with HFpEF conclusively. Thus outcomes related to HF therapies should be tested in 
specific populations. Also, while EMPA-REG OUTCOME trial was performed in patients with 
T2DM, the pharmacodynamics effects of empagliflozin lends itself to potentially also benefit 
patients with HF who do not have DM. 
  Based on these reasons, it is imperative to study this drug in adequately designed and 
powered dedicated HF clinical trials. This is of particular importance considering the 
increasing prevalence of patients with both HF and T2DM concomitantly. While this 
possibility remains, further studies to better understand the pharmacodynamic effects of 
SGLT inhibitors in patients with HF, including those without DM, are warranted. Importantly, 
 14 
larger outcomes trials are needed with these agents. These should of course also determine 
the safety of these agents including assessing rates of genital infection and ketosis risks, in 
particular.21 There are currently several phase III outcomes trials planned and just starting 
with empagliflozin and dapagliflozin. Empagliflozin will be studied in patients with HFpEF 
(EMPEROR-PRESERVED)90 and HFrEF (EMPEROR-REDUCED)91, including HF patients without 
T2DM with the composite primary endpoint of time to first event of adjudicated CV death or 
adjudicated HF. Dapagliflozin will be studied in patients with HFrEF (Dapa-HF)92 with the 
primary composite endpoint of CV death or hospitalization for HF or urgent HF visit as well 
as in patients with CKD (Dapa-CKD)93 Sotagliflozin and luseogliflozin, non-selective SGLT 1 
and 2 inhibitors, are also currently under development. (Table) 
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Figure 1. Comparison of mortality and heart failure hospitalization rates in the EMPAREG 
OUTCOME versus other trials 
Comparison of overall mortality (A) and heart failure hospitalization (B) rates between 
hypertension, heart failure preserved ejection fraction (HFpEF) heart failure reduced 
ejection fraction (HFrEF) trials with EMPAREG OUTCOME trial. Participants with heart failure 
in the EMPAREG OUTCOME trials had comparable risk to that seen in patients with HFpEF.  
 
ACCORD, Action to Control Cardiovascular Risk in Diabetes; LIFE, Losartan Intervention for Endpoint reduction 
in hypertension; ALLHAT, Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial; VALUE, 
Valsartan Antihypertensive Long-term Use Evaluation; ANBP-2, second Australian National, Losartan 
Intervention for Endpoint reduction in hypertension; CHARM-Preserved, CHARM-Added, CHARM-Alternative, 
Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity; I-PRESERVE, Irbesartan in 
Heart Failure with Preserved Systolic Function Trial; TOPCAT, Treatment of Preserved Cardiac Function Heart 
Failure with an Aldosterone Antagonist; PEP-CHF, Perindopril in elderly people with chronic heart failure; DIG-
PEF, Digitalis Investigation Group Congestive Heart Failure; PARADIGM-HF, Prospective comparison of ARNI 
with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure. 
 
Figure 2. Mechanism of Action of SGLT-2 inhibitors 
The sodium glucose cotransporter (SGLT)-2 inhibitor empagliflozin works primarily at the 
proximal convoluted tubule of the nephron inhibiting the reabsorption of glucose and 
sodium.  
 
Figure 3. Potential Pathways Linking Empagliflozin with Heart Failure Outcome 
Improvement 
CV, cardiovascular; HF, heart failure; HHF, hospitalization for heart failure; REG, removal of excess 
glucose; UNa, urinary sodium 
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Table. Ongoing Trials with SGLT-2 Inhibitors 
 
Drug Cohort Primary Endpoint 
Canagliflozin* 
 
 
Chronic HF Change from baseline aerobic 
exercise capacity at 12 weeks 
Change from baseline ventilator 
efficiency at 12 weeks 
Dapagliflozin* 
 
Chronic HF 
 
 
CKD 
Time to first occurrence of CV death 
or hospitalization for HF or urgent HF 
visit 
Time to first occurrence of ≥50% 
sustained decline in eGFR or reaching 
ESRD or CV death or renal death 
Empagliflozin* 
 
HFpEF 
HFrEF 
Time to first adjudicated CV death or 
adjudicated hospitalization for HF 
Luseogliflozin 
 
HFpEF Change in BNP at 12 weeks 
Ertugliflozin n/a n/a 
Sotagliflozin 
 
n/a n/a 
* Currently approved by Food and Drug Administration and European Medicines Agency 
BNP, b-type natriuretic peptide; CKD, chronic kidney disease; CV, cardiovascular; eGFR, 
estimated glomerular filtration rate; ESRD, end stage renal disease; HF, heart failure; HFpEF, 
heart failure preserved ejection fraction; HFrEF, heart failure reduced ejection fraction 
 
 
 
 
